Irbesartan Medical Valley (Irbesartan)

Irbesartan blocks the angiotensin II type 1 (AT1) receptor, preventing angiotensin II from causing vasoconstriction and aldosterone release. This results in relaxed blood vessels, reduced fluid retention, and lower blood pressure, while also protecting the kidneys from further damage.

The dose of Irbesartan Medical Valley is individualized by the prescribing clinician based on the patient’s condition, response, and renal function. Patients should follow the dosage instructions provided by their healthcare professional.

Irbesartan is classified as Pregnancy Category D, indicating potential risk to the fetus. It should be avoided during pregnancy. Limited data are available for breastfeeding; the decision to use it while nursing should be made by a physician after weighing benefits and risks.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and import documentation.

Irbesartan, an ARB, offers blood‑pressure control similar to ACE inhibitors but with a lower incidence of cough. Compared with calcium‑channel blockers or diuretics, it specifically targets the renin‑angiotensin pathway, making it useful for patients who also need renal protection.

Store Irbesartan Medical Valley at room temperature, below 25 °C, in the original packaging. Protect the product from moisture and direct sunlight to maintain its stability and potency.

Irbesartan Medical Valley is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless directed by a healthcare professional.

Serious risks include angioedema, severe hypotension, acute renal failure, hepatic injury, and hyperkalemia that can lead to cardiac arrhythmias. Patients should seek immediate medical attention if they experience swelling of the face or throat, rapid weight gain, or persistent dizziness.

Irbesartan should be avoided in patients with known hypersensitivity to the drug, severe hepatic impairment, or in women who are pregnant. Caution is also advised for individuals with significant renal dysfunction or those taking other medications that raise potassium levels.